Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Arginine methylation controls growth regulation by E2F-1
Ist Teil von
The EMBO journal, 2012-04, Vol.31 (7), p.1785-1797
Ort / Verlag
Chichester, UK: John Wiley & Sons, Ltd
Erscheinungsjahr
2012
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
E2F transcription factors are implicated in diverse cellular functions. The founding member, E2F‐1, is endowed with contradictory activities, being able to promote cell‐cycle progression and induce apoptosis. However, the mechanisms that underlie the opposing outcomes of E2F‐1 activation remain largely unknown. We show here that E2F‐1 is directly methylated by PRMT5 (protein arginine methyltransferase 5), and that arginine methylation is responsible for regulating its biochemical and functional properties, which impacts on E2F‐1‐dependent growth control. Thus, depleting PRMT5 causes increased E2F‐1 protein levels, which coincides with decreased growth rate and associated apoptosis. Arginine methylation influences E2F‐1 protein stability, and the enhanced transcription of a variety of downstream target genes reflects increased E2F‐1 DNA‐binding activity. Importantly, E2F‐1 is methylated in tumour cells, and a reduced level of methylation is evident under DNA damage conditions that allow E2F‐1 stabilization and give rise to apoptosis. Significantly, in a subgroup of colorectal cancer, high levels of PRMT5 frequently coincide with low levels of E2F‐1 and reflect a poor clinical outcome. Our results establish that arginine methylation regulates the biological activity of E2F‐1 activity, and raise the possibility that arginine methylation contributes to tumourigenesis by influencing the E2F pathway.
The transcription factor E2F‐1 regulates the cell cycle and apoptosis. E2F‐1 is arginine methylated by PRMT5, leading to degradation and increased cell growth. In colorectal cancer, high levels of PRMT5 correlate with low E2F‐1 and poor clinical outcome.